Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection

European Journal of Surgical Oncology

Volumn 34, Issue 3, 2008, Pages 333-338

  Chau, G Y ^a   Lui, W Y ^a   Chi, C W ^a   Chau, Y P ^b   Li, A F ^a   Kao, H L ^a   Wu, C W ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

C met receptor; Hepatectomy; Hepatocellular carcinoma; Hepatocyte growth factor; Prognosis

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MITOGENESIS; PERIPHERAL CIRCULATION; PORTAL VEIN BLOOD FLOW; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

CARCINOMA, HEPATOCELLULAR; HEPATECTOMY; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 40049092502     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.12.007     Document Type: Article

References (30)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and non-surgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32 (2000) 1224-1229
3. Chang C.H., Chau G.Y., Lui W.Y., Tsay S.H., King K.L., and Wu C.W. Long-term results of hepatic resection for hepatocellular carcinoma originating from the non-cirrhotic liver. Arch Surg 139 (2004) 320-325
4. Poon R.T.P., Fan S.T., and Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232 (2000) 10-24
5. Chau G.Y., Lui W.Y., and Wu C.W. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am 12 (2003) 25-34
6. Gohda E., Tsubouchi H., Nakayama H., et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 81 (1988) 414-419
7. Yanagita K., Nagaike M., Ishibashi H., Niho Y., Matsumoto K., and Nakamura T. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun 182 (1992) 802-809
8. Noji S., Tashiro K., Koyama E., et al. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun 173 (1990) 42-47
9. Matsumoto K., and Nakamura T. Hepatocyte growth factors: molecular structure and implications for a central role in liver regeneration. J Gastroenterol Hepatol 6 (1991) 509-519
10. Ljubimova J.Y., Petrovic L.M., Wilson S.E., Geller S.A., and Demetriou A.A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45 (1997) 79-87
11. Shiota G., Okano J., Kawasaki H., Kawamoto T., and Nakamura T. Serum hepatocyte growth factor levels in liver disease: clinical implication. Hepatology 21 (1995) 106-112
12. Matsumoto K., Nakamura T., and Kramer R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 269 (1994) 31807-31813
13. Neaud V., Faouzi S., Guirouilh J., et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 26 (1997) 1458-1466
14. Monvoisin A., Neaud V., De Ledinghen V., et al. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 30 (1999) 511-518
15. Junbo H., Li Q., Zaide W., and Yunde H. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo 13 (1999) 177-180
16. Yamazaki H., Oi H., Matsumoto K., et al. Biphasic changes in serum hepatocyte growth factor after transarterial chemoembolization therapy for hepatocellular carcinoma. Cytokine 8 (1996) 178-182
17. Wu F., Wu L., Zheng S., et al. The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis 38 (2006) 490-497
18. Lindroos P.M., Zarnegar R., and Michalopoulos G.K. Hepatocyte growth factor (hepatopoietin A) rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial hepatectomy and carbon tetrachloride administration. Hepatology 13 (1991) 743-749
19. Tomiya T., Tani M., Yamada S., Hayashi S., Umeda N., and Fujiwara K. Serum hepatocyte growth factor levels in hepatectomized and non-hepatectomized surgical patients. Gastroenterology 103 (1992) 1621-1624
20. Selden C., Johnstone R., Darby H., Gupta S., and Hodgson H.J. Human serum does contain a high molecular weight hepatocyte growth factor: studies pre-and post-hepatic resection. Biochem Biophys Res Commun 139 (1986) 361-366
21. Higaki I., Yamazaki O., Matsuyama M., et al. Portal serum human hepatocyte growth factor levels after partial hepatectomy. Hepatogastroenterology 46 (1999) 1078-1082
22. Tsai T.J., Chau G.Y., Lui W.Y., et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127 (2000) 603-608
23. Tsubouchi H. Hepatocyte growth factor for liver disease. Hepatology 30 (1999) 333-334
24. Selden C., Farnaud S., Ding S.F., Habib N., Foster C., and Hodgson H.J. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumors. J Hepatol 21 (1994) 227-234
25. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). Liver including intrahepatic bile ducts. In: American Joint Committee on Cancer Staging Manual. 6th ed. (2002), Springer, New York 131-144
26. Yamagamim H., Moriyama M., Matsumura H., et al. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 95 (2002) 824-834
27. Noguchi O., Enomoto N., Ikeda T., Kobayashi F., Marumo F., and Sato C. Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. J Hepatol 24 (1996) 286-292
28. Nagata K., Hirono S., Ido A., et al. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 289 (2001) 205-211
29. De Ledinghen V., Monvoisin A., Neaud V., et al. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int J Oncol 19 (2001) 83-88
30. Heideman D.A., Overmeer R.M., van Beusechem V.W., et al. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther 12 (2005) 954-962